The FDA has granted priority review to a non-opioid, postoperative pain treatment, HTX-011…... [Read More]
FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones
Search results for: fluoroquinolones
Rheumatology Drug Updates: Labeling for Fluoroquinolones; FDA to Review Benzhydrocodone/Acetaminophen Combination
FDA Restricts Fluoroquinolone Use The U.S. Food and Drug Administration (FDA) has twice previously communicated safety information about systemic fluoroquinolones—in August 2013 and July 2008. The safety issues of this medication class described in its latest Drug Safety Communication were also discussed at a November 2015 FDA Advisory Committee meeting.1 The FDA is now advising… [Read More]
FDA Restricts Use of Systemic Fluoroquinolones Due to Side Effects & Will Review Application of Apadaz for Pain
The FDA has issued new safety guidelines for systemic fluoroquinolones, restricting their use to patients with no alternative treatment options…... [Read More]
Case Report: Metoprolol-Induced Arthralgia
Various drugs are known to cause musculoskeletal symptoms, such as arthralgias, myalgias, drug-induced lupus and serum sickness.1 In the rheumatology world, the most commonly recognized drugs that can cause musculoskeletal symptoms are hydralazine, minocycline, fluoroquinolones and, recently, the dipeptidyl peptidase 4 (DPP-4) inhibitor class of medications. Although beta blockers also have a noted side effect… [Read More]
Shorter Antibiotic Therapy Effective for Pyogenic Vertebral Osteomyelitis
Six-week treatment regimen returns same results as 12 weeks in recent study, although researchers caution findings may not apply to all patients with vertebral osteomyelitis... [Read More]
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety... [Read More]